Patents by Inventor James Martin Staddon

James Martin Staddon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-PT217 TAU ANTIBODY
    Publication number: 20240076361
    Abstract: Disclosed herein an anti-pT217 Tau antibody or a pT217 Tau-binding fragment thereof.
    Type: Application
    Filed: February 17, 2022
    Publication date: March 7, 2024
    Inventors: Sonia CIEZAREK, Malcolm Ian ROBERTS, James Martin STADDON, Takashi OBARA, Yohei MUKAI, Lal Kishan AGARWALA
  • ANTI-TAU ANTIBODIES AND USES THEREOF
    Publication number: 20240034777
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Application
    Filed: January 4, 2023
    Publication date: February 1, 2024
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Anti-Tau antibodies and uses thereof
    Patent number: 11578120
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Grant
    Filed: September 24, 2020
    Date of Patent: February 14, 2023
    Assignees: Eisai R&D Management Co., Ltd., UCL Business LTD
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • ANTI-TAU ANTIBODIES AND USES THEREOF
    Publication number: 20210024622
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Application
    Filed: September 24, 2020
    Publication date: January 28, 2021
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Anti-tau antibodies and uses thereof
    Patent number: 10829547
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: November 10, 2020
    Assignees: Eisai R&D Management Co., Ltd., UCL Business LTD
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Anti-Tau antibodies and uses thereof
    Patent number: 10358485
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: July 23, 2019
    Assignees: Eisai R&D Management Co., Ltd., UCL Business PLC
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • ANTI-TAU ANTIBODIES AND USES THEREOF
    Publication number: 20190112365
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Application
    Filed: December 12, 2018
    Publication date: April 18, 2019
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • ANTI-TAU ANTIBODIES AND USES THEREOF
    Publication number: 20190112364
    Abstract: Provided herein are antibodies that specifically bind Tau and methods of using the same.
    Type: Application
    Filed: October 16, 2018
    Publication date: April 18, 2019
    Inventors: Malcolm Ian Roberts, James Martin Staddon, Hettihewage Alfred Rohan De Silva, Jared Spidel, Hirofumi Aoyagi, Shigeru Akasofu, Yutaka Hashizume, Kishan Agarwala
  • Modifying the permeability of physiological barriers
    Publication number: 20020142943
    Abstract: The degree of phosphorylation of serine and threonine residues of p100/p120 can affect the permeability of physiological barriers and also cell-cell adhesion properties. By changing physiological levels, various disorders can be treated, including multiple sclerosis, cancer, head injuries, oedema, stroke, inflammation and gastric ulcers. Furthermore, drugs can be allowed to pass across physiological barriers and the barriers can then be closed.
    Type: Application
    Filed: May 24, 2002
    Publication date: October 3, 2002
    Applicant: Eisai Co., Limited
    Inventors: James Martin Staddon, Mary Louise Morgan, Marianne Jennifer Ratcliffe
  • Modifying the permeability of physiological barriers
    Patent number: 6407058
    Abstract: The degree of phosphorylation of serine and threonine residues of p100/p120 can affect the permeability of physiological barriers and also cell—cell adhesion properties. By changing physiological levels, various disorders can be treated, including multiple sclerosis, cancer, head injuries, oedema, stroke, inflammation and gastric ulcers. Furthermore, drugs can be allowed to pass across physiological barriers and the barriers can then be closed.
    Type: Grant
    Filed: March 29, 1999
    Date of Patent: June 18, 2002
    Assignee: Eisai Co., Limited
    Inventors: James Martin Staddon, Mary Louise Morgan, Marianne Jennifer Ratcliffe
  • Modulating the permeability of a physiological barrier with an agent that modulates tyrosine phosphorylation
    Patent number: 6312686
    Abstract: Permeability of the blood-brain barrier and other physiological barriers can be modulated by the degree of tyrosine phosphorylation of proteins. Agents which promote tyrosine protein dephosphorylation reduce the permeability of the blood-brain barrier and those which promote phosphorylation increase permeability. Increasing blood-brain barrier permeability is useful in delivering drugs having a desired effect upon the central nervous system; decreasing blood-brain barrier permeability and other physiological barrier permeability is useful in preventing undesired compounds reaching the CNS and in certain clinical conditions.
    Type: Grant
    Filed: December 23, 1997
    Date of Patent: November 6, 2001
    Assignee: Eisai Co., Ltd.
    Inventors: James Martin Staddon, Lee Laurence Rubin, Kurt Herrenknecht, Mary Louise Morgan
  • Proteins involved in the regulation of cell—cell adhesion and uses thereof
    Patent number: 6245888
    Abstract: A protein, p100, is disclosed having a molecular weight of about 100 kDa, being associated in vivo with catenin-cadherin complex of epithelial or endothelial cells, and having cross-reactivity with an antibody to the p120 protein involved in cell-cell adhesion. Also disclosed is a method to treat a cancer or developmental disorder characterized by compromised cell-cell adhesion.
    Type: Grant
    Filed: May 19, 1997
    Date of Patent: June 12, 2001
    Assignee: Eisai Co., Ltd.
    Inventor: James Martin Staddon